| Literature DB >> 29710865 |
Yaqi Wang1,2, Jiaojiao Jiao3, Yuanzhen Yang4, Ming Yang5,6, Qin Zheng7.
Abstract
The method of cell biospecific extraction coupled with UPLC/Q-TOF-MS has been developed as a tool for the screening and identification of potential immunological active components from Andrographis Herba (AH). In our study, a macrophage cell line (RAW264.7) was used to extract cell-combining compounds from the ethanol extract of AH. The cell binding system was then analyzed and identified by UPLC/Q-TOF-MS analysis. Finally, nine compounds, which could combine with macrophages, in an ethanol extract of AH were detected by comparing basic peak intensity (BPI) profiles of macrophages before and after treatment with AH. Then they were identified as Andrographidine E (1), Andrographidine D (2), Neoandrographolide (3), Dehydroandrographolide (4), 5, 7, 2′, 3′-tetramethoxyflavone (5), β-sitosterol (7), 5-hydroxy-7, 2′, 3′-trimethoxyflavone (8) and 5-hydroxy-7, 8, 2′, 3′-tetramethoxyflavone (9), which could classified into five flavonoids, three diterpene lactones, and one sterol. Their structures were recognized by their characteristic fragment ions and fragmentations pattern of diterpene lactones and flavonoids. Additionally, the activity of compounds 3, 4, and 7 was tested in vitro. Results showed that these three compounds could decrease the release of NO (p < 0.01) in macrophages remarkably. Moreover, 3, 4, and 7 showed satisfactory dose-effect relationships and their IC50 values were 9.03, 18.18, and 13.76 μg/mL, respectively. This study is the first reported work on the screening of immunological active components from AH. The potential immunological activity of flavonoids from AH has not been reported previously.Entities:
Keywords: Andrographis paniculata; UPLC/Q-TOF-MS; cell biospecific extraction; immunological activity
Mesh:
Substances:
Year: 2018 PMID: 29710865 PMCID: PMC6102597 DOI: 10.3390/molecules23051047
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structures of compounds identified in the cell extract of Andrographis Herba (AH). (1. Andrographidine E, 2. Andrographidine D, 3. Neoandrographolide, 4. Dehydroandrographolide, 5. 5,7,2′,3′-tetramethoxyflavone, 7. β-sitosterol, 8. 5-hydroxy-7,2′,3′-trimethoxyflavone, 9. 5-hydroxy-7,8,2′,3′-tetramethoxyflavone).
Figure 2Base peak intensity (BPI) profiles of: (A) extract of AH treated with macrophages; (B) extract of denatured deposited macrophages; (C) ethanol extract of AH.
Characteristics of potential bioactive compounds from AH by UPLC/Q-TOF-MS.
| No. | tR | Molecular Formula | Molecular Ions | Fragments | Identification |
|---|---|---|---|---|---|
| 1 | 8.5 | C24H26O11 | 491.1540 [M + H]+ | 329.1012 [M + H − Glc]+ | Andrographidine E |
| 2 | 8.9 | C25H28O12 | 521.1649 [M + H]+ | 359.1119 [M + H − Glc]+ | Andrographidine D |
| 3 | 10.2 | C26H40O8 | 481.2791 [M + H]+ | 319.2259 [M + H − Glc]+ | Neoandrographolide |
| 4 | 12.4 | C20H28O4 | 333.2058 [M + H]+ | 315.1953 [M + H − H2O]+ | Dehydroandrographolide |
| 5 | 13.0 | C19H18O6 | 343.1170 [M + H]+ | 328.0942 [M + H − CH3]+ | 5,7,2′,3′-tetramethoxyflavone |
| 6 | 13.5 | C21H30O6 | 379.2474 [M + H]+ | 361.2369 [M + H − H2O]+ | Unknown |
| 7 | 18.8 | C29H50O | 415.2109 [M + H]+ | Typical fragment 135.0802 | β-sitosterol |
| 8 | 19.7 | C18H16O6 | 329.1010 [M + H]+ | 314.0775 [M + H − CH3]+ | 5-hydroxy-7, 2′, 3′-trimethoxyflavone |
| 9 | 20.0 | C19H18O7 | 359.1116 [M + H]+ | 344.0890 [M + H − CH3]+ | 5-hydroxy-7, 8,2′,3′-tetramethoxyflavone |
Figure 3MS/MS spectra of andrographidine E (1).
Figure 4The proposed fragmentations pattern of andrographidine E (1).
Figure 5MS/MS spectra of neoandrographolide (3).
Figure 6The proposed fragmentations pattern of neoandrographolide (3).
Effects of compounds 3, 4, and 7 on LPS-induced NO release of macrophages 1.
| Groups | NO Level (μmol/L) | NO Inhibition (% of LPS) | NO IC50 (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 | 4 | 7 | 3 | 4 | 7 | 3 | 4 | 7 | |
| Normal control (cells only) | 0.52 ± 0.07 | 0.81 ± 0.11 | 0.58 ± 0.08 | (-) | (-) | (-) | |||
| LPS alone | 13.46 ± 1.80 ** | 33.45 ± 0.76 ** | 17.90 ± 1.20 ** | (-) | (-) | (-) | |||
| LPS/drug (1.25 μg/mL) | 11.68 ± 0.41 | 32.29 ± 1.22 | 17.59 ± 0.28 | 5.79 ± 0.80 | 5.79 ± 0.80 | 3.34 ± 0.28 | 9.03 | 18.18 |
|
| LPS/drug (2.50 μg/mL) | 11.01 ± 0.31 | 29.81 ± 2.11 ## | 16.81 ± 0.81 | 13.71 ± 1.08 | 13.71 ± 1.08 | 9.64 ± 1.12 | |||
| LPS/drug (5.00 μg/mL) | 9.28 ± 1.29 ## | 29.06 ± 0.65 ## | 12.49 ± 1.67 ## | 13.13 ± 1.94 | 13.13 ± 1.94 | 38.42 ± 1.75 | |||
| LPS/drug (10.00 μg/mL) | 5.79 ± 0.79 ## | 24.07 ± 0.60 ## | 9.74 ± 0.89 ## | 28.04 ± 1.80 | 28.04 ± 1.80 | 45.59 ± 4.96 | |||
| LPS/drug (20.00 μg/mL) | 1.95 ± 0.24 ## | 15.70 ± 1.58 ## | 3.56 ± 0.47 ## | 53.06 ± 4.72 | 53.06 ± 4.72 | 80.09 ± 2.63 | |||
** p < 0.01 vs. normal control group. ## p < 0.01 vs. LPS alone group.